References
- Cottin V. Eosinophilic lung diseases. Clin Chest Med. [Internet]. 2016;37(3):535–556.
- De Giacomi F, Vassallo R, Yi ES, et al. Acute eosinophilic pneumonia. Am J Respir Crit Care Med. 2018;197(6):728–736.
- Rhee CK, Min KH, Yim NY, et al. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J. 2013;41(2):402–409.
- Higashi Y, Nakamura S, Tsuji Y, et al. Daptomycin-induced eosinophilic pneumonia and a review of the published literature. Intern Med. 2018;57(2):253–258.
- US Food and Drug Administration. FDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm
- Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35:447–457.
- Uppal P, LaPlante KL, Gaitanis MM, et al. Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control. 2016;5(55). DOI:10.1186/s13756-016-0158-8
- Heidary M, Khosravi AD, Khoshnood S, et al. Daptomycin. J Antimicrob Chemother. 2018;73(1):1–11.
- Package insert. Cubicin (daptomycin) injection, cubist pharmaceuticals, Lexington, MA, November 2010.
- Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia. Medicine. 2018;97:4.
- Patel JJ, Antony A, Herrera M, et al. Daptomycin-induced acute eosinophilic pneumonia. Wis Med J. 2014;113(5):199–201.
- Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152.
- Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int. Internet. 2019;68(4):413–419.
- Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis. 2010;50(5):737–740.